These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23355629)

  • 1. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial.
    Iseki K; Arima H; Kohagura K; Komiya I; Ueda S; Tokuyama K; Shiohira Y; Uehara H; Toma S;
    Nephrol Dial Transplant; 2013 Jun; 28(6):1579-89. PubMed ID: 23355629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
    Suzuki H; Kanno Y; Sugahara S; Ikeda N; Shoda J; Takenaka T; Inoue T; Araki R
    Am J Kidney Dis; 2008 Sep; 52(3):501-6. PubMed ID: 18653268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
    Sakata Y; Shiba N; Takahashi J; Miyata S; Nochioka K; Miura M; Takada T; Saga C; Shinozaki T; Sugi M; Nakagawa M; Sekiguchi N; Komaru T; Kato A; Fukuchi M; Nozaki E; Hiramoto T; Inoue K; Goto T; Ohe M; Tamaki K; Ibayashi S; Ishide N; Maruyama Y; Tsuji I; Shimokawa H; ;
    Eur Heart J; 2015 Apr; 36(15):915-23. PubMed ID: 25637937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial--rationale and design.
    Sakata Y; Nochioka K; Miura M; Takada T; Tadaki S; Miyata S; Shiba N; Shimokawa H
    J Cardiol; 2013 Jul; 62(1):31-6. PubMed ID: 23769179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
    Haller H; Ito S; Izzo JL; Januszewicz A; Katayama S; Menne J; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G;
    N Engl J Med; 2011 Mar; 364(10):907-17. PubMed ID: 21388309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study.
    Takahashi A; Takase H; Toriyama T; Sugiura T; Kurita Y; Ueda R; Dohi Y
    Nephrol Dial Transplant; 2006 Sep; 21(9):2507-12. PubMed ID: 16766543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
    Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H;
    Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
    Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
    Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.
    Imai E; Chan JC; Ito S; Yamasaki T; Kobayashi F; Haneda M; Makino H;
    Diabetologia; 2011 Dec; 54(12):2978-86. PubMed ID: 21993710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial.
    Ogihara T; Saruta T; Rakugi H; Saito I; Shimamoto K; Matsuoka H; Shimada K; Ito S; Horiuchi M; Imaizumi T; Takishita S; Higaki J; Katayama S; Kimura G; Umemura S; Ura N; Hayashi K; Odawara M; Tanahashi N; Ishimitsu T; Kashihara N; Morita S; Teramukai S;
    J Hypertens; 2014 Oct; 32(10):2054-63; discussiom 2063. PubMed ID: 24999799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis.
    Fang W; Oreopoulos DG; Bargman JM
    Nephrol Dial Transplant; 2008 Nov; 23(11):3704-10. PubMed ID: 18567695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study.
    Padwal R; Lin M; Etminan M; Eurich DT
    Hypertension; 2014 May; 63(5):977-83. PubMed ID: 24535009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
    Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
    Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors.
    Walker AM; Liang C; Clifford CR; Parker C; Feldman A
    Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):348-56. PubMed ID: 24375940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus.
    Fogari R; Derosa G; Zoppi A; Rinaldi A; Preti P; Lazzari P; Mugellini A
    Hypertens Res; 2008 Jan; 31(1):43-50. PubMed ID: 18360017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.